Skip to main
ANL

ANL Stock Forecast & Price Target

ANL Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adlai Nortye is a clinical-stage company developing promising cancer therapies, including the RAS-targeting drug AN9025, with potential for 180% growth according to analysts. Despite potential competition and concerns over toxicities, AN9025 has shown strong preclinical data and has a strategic partnership for development in China. Adlai's second drug, AN4035, has shown potential as a targeted antibody drug conjugate, and the company has a promising valuation and potential for growth in the near future.

Bears say

Adlai Nortye is a clinical-stage company developing cancer therapies that may face challenges in generating significant revenue from commercializing its product candidates. With a limited competitive landscape in the 1L mPDAC market, and challenges with response rates and resistances seen in similar RAS-targeting therapies, Adlai's pan-RAS and immunotherapy candidates may have a less compelling profile than its competitors. Additionally, while Adlai's financial position may support clinical development for its pipeline, its late entry into the market and potential safety concerns may limit its success in the future.

ANL has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adlai Nortye Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adlai Nortye Ltd (ANL) Forecast

Analysts have given ANL a Strong Buy based on their latest research and market trends.

According to 3 analysts, ANL has a Strong Buy consensus rating as of Jun 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adlai Nortye Ltd (ANL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.